TENAX THERAPEUTICS, INC. — Form 8-K
Filed September 9, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Tenax's Phase 3 LEVEL trial of oral levosimendan (TNX-103) for PH-HFpEF failed its primary endpoint (6-minute walk distance [6MWD] improvement: 3.5 m vs placebo, p=0.63). However, in pre-specified subgroup analysis, patients with baseline 6MWD ≤333 m showed +26.3 m improvement vs placebo (p=0.0112). NT-proBNP fell 49% vs placebo (p=0.0001); right ventricular systolic pressure declined 4.9 mmHg (p=0.0090). Safety profile was acceptable with dose-limiting headache, palpitations, and hypotension. Tenax plans to enrich LEVEL-2 entry criteria to favor sicker patients with lower baseline 6MWD.
Why this rating
Trial miss on primary endpoint is negative for stock; however, biomarker improvements (NT-proBNP -49%) and meaningful efficacy in sicker subgroup (26 m in ICH-GCP–relevant cohort) de-risk LEVEL-2. For $23.8M-cap company, a Phase 3 program continuation with refined patient selection is strategically material but outcome remains uncertain.
Price action (we called it neutral)
before filing · preread $2.07 ▲ 4.55% | at our read · unknown $1.98 | +10 min · unknown $1.98 ▲ 0.00% | +30 min · unknown $1.98 ▲ 0.00% | +1 hr pending | +4 hrs pending |
The stock had already moved -4.35% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.